Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116437 | 0.92 | PTGS2 (0.66) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL10421964 | 0.91 | PTGS2 (0.51) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL9543814 | 0.90 | PTGS2 (0.54) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL5908176 | 0.88 | GAA (0.63) | PTGS2ALDH1A1CYP2C9CYP2C19GAA | |
| SCHEMBL1507822 | 0.88 | PTGS2 (0.49) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL12061812 | 0.86 | GAA (0.66) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL17365269 | 0.86 | PTGS2 (0.60) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL10364396 | 0.84 | PTGS2 (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL4264046 | 0.84 | PTGS2 (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL7693991 | 0.84 | PTGS2 (0.58) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993001824-A1 | COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS | BAYLOR COLLEGE OF MEDICINE (US) | 1993-02-04 | — | — | WO | claimed |
| EP-0374184-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. | BAYLOR COLLEGE MEDICINE (US) | 1990-06-27 | — | — | EP | claimed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | claimed |
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| WO-2019189419-A1 | ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| EP-2184277-B1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-07-01 | — | — | EP | disclosed |
| US-8759355-B2 | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-8759355-B2 | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-8436201-B2 | Functionalized diphenolics and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436201-B2 | Functionalized diphenolics and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-05-07 | — | — | US | disclosed |
| EP-0459702-A1 | Azole Derivatives | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-5037991-A | Insecticides | SANDOZ LTD. (CH) | 1991-08-06 | — | — | US | disclosed |
| US-4968829-A | ANTHELMINTICS, PARASITICIDES, NEMATOCIDES | SANDOZ LTD. (CH) | 1990-11-06 | — | — | US | disclosed |
| EP-0129851-B1 | PREPARATION OF MONOALKYLATED DIHYDROXYBENZENES AND NOVEL COMPOUNDS PREPARED THEREBY | THE DOW CHEMICAL COMPANY (US) | 1988-07-13 | — | — | EP | disclosed |
| US-4691042-A | Preparation of monaoalkylated dihydroxybenzenes and novel compounds prepared thereby | THE DOW CHEMICAL COMPANY (US) | 1987-09-01 | — | — | US | disclosed |
| US-4568497-A | Preparation of monoalkylated dihydroxybenzenes | THE DOW CHEMICAL COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4511731-A | 2-Ethoxyethyl 2-(4-hydroxyphenoxy)-propanoate | THE DOW CHEMICAL COMPANY (US) | 1985-04-16 | — | — | US | disclosed |
| EP-0129851-A2 | Preparation of monoalkylated dihydroxybenzenes and novel compounds prepared thereby | THE DOW CHEMICAL COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4310527-A | DISORDERS OF CAROIAC RHYTHM AND CORONARY HEART DISEASES AND HYDPERTENSION | CIBA-GEIGY CORPORATION (US) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | PTGS2 2582/4885ALDH1A1 333/4885CYP2C9 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.